Active	Status	Sponsor type	Region	Phase	Filter
2 Active 3 Inactive 5 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

2 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Eskens, Ferry ALM
NCT05584670 / 2022-001239-95: A First-in-human, Dose Escalation and Dose Expansion Study of SAR445877 in Adult Participants With Advanced Solid Tumors	Recruiting	1/2	285	Europe, US, RoW	SAR445877, Cetuximab, Erbitux	Sanofi, Sanofi Aventis Recherche & Développement	Solid Tumor	01/27	09/28
REACtiVe-2, NCT05650918: MesoPher/Mitazalimab-combination Therapy in Metastatic Pancreatic Disease ( Trial)	Completed	1	22	Europe	MesoPher, Mitazalimab	Joachim Aerts, MD PhD	Metastatic Pancreatic Cancer	05/23	05/23